Bullish Views for XPeng and Blueprint Medicines
- August 21st, 2023
- 442 views
XPeng Inc. (NYSE: XPEV), a leading Chinese electric vehicle manufacturer, received a boost in investor sentiment as BofA Securities upgraded the company from Neutral to Buy and raised the price target from $16.30 to $22.00.
Considering that $XPEV closed at $14.98 on Friday, the adjusted price target indicates a potential upside of $7.02 or approximately 46.83%, based on the financial advisory firm's assessment
In other news, Blueprint Medicines Corporation (Nasdaq: BPMC) continues to receive a favorable evaluation from Needham, as the brokerage firm maintained its Buy rating and raised the price target from $65 to $66.
Based on Friday's closing price of $49.29, the updated price target implies a potential upside of $16.71 or approximately 33.88% for $BPMC, according to Needham's analysis.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
FDA Approves Nerve Scaffold for the Treatment of Sensory Nerve Discontinuity
December 04th, 2025December 02nd, 2025Earnings Countdown: Salesforce, Snowflake, and Guidewire Take Center Stage
November 30th, 2025Wall Street Eyes CrowdStrike, Marvell Technology, and GitLab as Earnings Near
November 30th, 2025Earnings Preview: Credo Technology, MongoDB, and Hafnia in Focus
November 30th, 2025




Member Login